首页 > 市场调查报告书 > 医疗设备

病患监测

市场调查报告书

商品编码

1345412

全球脑电图设备市场 - 2023-2030

Global Electroencephalography Devices Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球脑电图设备市场于 2022 年达到 13 亿美元，预计到 2030 年将达到 26 亿美元，2023-2030 年预测期间复合年增长率为 9.4%。

脑电图 (EEG) 是一种利用固定在头皮上的小型金属盘（电极）来估计大脑电活动的检查。脑细胞通过电刺激进行交流，并且始终处于活动状态，这是睡眠的不变量。这一运动在脑电图记录上呈现出波浪线。脑电图的主要好处是检测和检查癫痫症，这是一种诱发反復发作的疾病。

脑电图有望帮助医生查明患者可能患有的癫痫类型、可能引发癫痫发作的原因以及如何令人满意地治疗该病症。偶尔，脑电图可用于检查不同的疾病，如痴呆、头部受伤和外伤、脑肿瘤、脑炎（脑部炎症）和睡眠疾病，包括睡眠呼吸暂停。

神经系统疾病病例的不断增加，以及收购、兼併、合作、产品发布、产品批准、收购和扩张等市场发展的不断增加，是预计将推动全球脑电图设备市场增长的其他主要因素。预测期。此外，脑电图设备不断增长的研究活动和技术进步预计也将有助于预测期内的全球市场增长。

动力学

神经系统疾病的患病率不断增加

阿尔茨海默病、癫痫、痴呆、多发性硬化症、帕金森病和中风等神经系统疾病的日益流行预计将推动全球市场的增长。例如，根据世界卫生组织 2023 年的数据，全球约有 5000 万人患有癫痫症，使其成为全球最典型的神经系统疾病之一。大约 80% 的癫痫患者生活在低收入和中等收入国家。

据评估，如果诊断和治疗得当，大约 70% 的癫痫患者可以无癫痫发作。此外，根据 Cure Epilepsy 的数据，美国每年在癫痫方面的支出约为 155 亿美元。此外，根据世界卫生组织2023的数据，目前全球有超过5500万痴呆症患者，其中60%以上生活在低收入和中等收入国家。

每年都会发现超过 1000 万新的痴呆症病例。痴呆症是由影响大脑的疾病和损伤共同引起的。阿尔茨海默病是最典型的痴呆症，可能占病例的 60-70%。同样，据阿尔茨海默病协会估计，全球患有 AD 痴呆、前驱 AD 和临床前 AD 的人数分别为 32、69 和 3.15 亿。他们在 AD 连续体中总共占 4.16 亿人，占所有 50 岁及以上人口的 22%。

产品批准和发布数量不断增加

不同监管机构批准商业化和产品引入市场的产品数量不断增加，预计将推动预测期内全球市场的增长。例如，2022 年 8 月，计算 QEEG 分析领域的全球领导者 Myneurva 推出了 Starrbase，这是一种完全集成的系统高级神经网络分析 EEG 设备。

此外，2021 年11 月，Brain Scientific 的下一代NeuroCap 脑电图耳机是一种前卫的脑电图(EEG) 电极阵列，用于在常规临床和研究环境中快速获取脑电图，其中STAT 脑电图的记录获得了美国食品和药物管理局的支持赞同。 2022 年 9 月，美国食品和药物管理局 (FDA) 再次授予 Ceribell, Inc. 的谵妄适应症突破性设备称号，该系统采用机器学习来检查脑电图 (EEG) 信号以诊断谵妄。

此外，2022 年 10 月，Nihon Kohden 推出了智能电缆 NMT Pod 和一次性电极，这是一种具有智能电缆程序的仪器。这项开发使临床医生能够在手术时向患者给予神经肌肉阻滞剂（NMBA）（去极化或非去极化）时精确扫描患者的瘫痪深度。

脑电图设备成本高

设备的成本根据其灵敏度、精度和模式的特点而有所不同。例如，较低的价格范围（99 美元 - 1,000 美元）从最低数量的电极开始。儘管有研究潜力，但像 NeuroSky 和 Muse 这样的公司很少承诺神经反馈并提供低成本的解决方案来帮助改善冥想和睡眠。而中间价格范围（1,000 美元 - 25,000 美元）为每个设备提供更多可用电极，并对硬件单元提供额外奖励。该价格范围内的所有设备都是研究级的，但是，研究的精确性质将指定哪种设备最适合该目的。

许多公司（ABM、ANT Neuro、Cognionics、G.tec、mBrainTrain、Neuroelectrics 和 Wearable Sensing）都在此价格范围内提供无线设备，通过改善移动性和增加舒适度来促进数据收集。此外，较高的价格范围（25,000 美元以上）可提供大量电极通道，使用 Brain Product 的 ActiCHamp 时可提供 32 个通道，使用 BioSemi 时可恢復至 160 个甚至 256 个通道。如此丰富的电极可以在检测大脑信号时显着提高分辨率。然而，这些设备的高成本使得低收入者难以负担得起，从而减少了高端设备市场需求并减缓了市场增长。

神经科医生劳动力短缺

预计神经科医生劳动力的巨大缺口将阻碍预测期间全球脑电图设备市场的增长。例如，英国神经病学家协会（ABN）发布的数据表明，英国顾问神经病学家的劳动力数量大大低于预期。与法国和德国相比，英国的劳动力水平在很大程度上处于劣势，即使是在伦敦和邻近地区，患者与顾问的比例更为合理。 ABN 最近进行了一项劳动力调查，调查了近一半的神经科顾问医生，占总数的 46%，以及超过三分之一的神经科实习生，占总数的 35%。

此外，ABN 还发现，负责患者援助的全职等效 (FTE) 神经病学顾问的比例为每 100,000 人 1.1 人，即每 91,175 名居民 1 人。这与以下事实无关：英国的医师队伍密度适中，据世界卫生组织 (WHO) 估计，每 10,000 名居民中有 28 名医生。此外，2019 年，仅有 400 名神经科医师开放预约。这一数字已大幅上升，预计到 2025 年，神经科医生劳动力缺口将达到 19%。

Overview

Global Electroencephalography Devices Market reached US$ 1.3 billion in 2022 and is expected to reach US$ 2.6 billion by 2030, growing with a CAGR of 9.4% during the forecast period 2023-2030.

An electroencephalogram (EEG) is an examination that estimates electrical activity in the brain utilizing small, metal discs (electrodes) affixed to the scalp. Brain cells communicate through electrical stimulations and are active all the time, an invariant of sleep. This movement exhibits wavy lines on an EEG recording. The principal benefit of an EEG is to detect and examine epilepsy, a disorder that induces repeated episodes.

An EEG is expected to aid the physician pinpoint the class of epilepsy that the patient may hold, what may be initiating the episodes, and how satisfactorily treat the condition. Less frequently, an EEG might be employed to examine different conditions, like dementia, head injury and trauma, brain tumors, encephalitis (brain inflammation), and sleep ailments, including sleep apnoea.

The growing cases of neurological disorders, and increasing market developments such as acquisitions, mergers, collaborations, product launches, product approvals, takeovers, and expansion among others are among the other primary factors that are expected to boost the global Electroencephalography Devices market growth in the forecast period. Further, the growing research activities and technological advancements in Electroencephalography Devices are also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Prevalence of Neurological Disorders

The increasing prevalence of neurological disorders such as Alzheimer's, epilepsy, dementia, multiple sclerosis, Parkinson's disease, and stroke among others are expected to drive the global market growth. For instance, according to WHO 2023, around 50 million individuals globally suffer from epilepsy, making it among the most typical neurological disorders worldwide. Approximately 80% of individuals with epilepsy live in low- and middle-income nations.

It is assessed that about 70% of individuals living with epilepsy could live seizure-free if appropriately diagnosed and treated. Further, according to Cure Epilepsy, the United States expends roughly $15.5 billion on epilepsy annually. Moreover, according to the WHO 2023, presently, more than 55 million individuals with dementia globally out of which more than 60% of whom live in low-and middle-income nations.

Each year, over 10 million new cases of dementia are detected. Dementia results from a combination of disorders and injuries that affect the brain. Alzheimer's disease is the most typical state of dementia and may account for 60-70% of cases. Similarly, according to the Alzheimer's Association, estimations the global number of individuals with AD dementia, prodromal AD, and preclinical AD were 32, 69, and 315 million, respectively. Jointly they accounted for 416 million across the AD continuum or 22% of all individuals aged 50 and above.

Increasing Number of Product Approvals and Launches

The increasing number of product approvals from distinct regulatory bodies for commercialization and product introduction into the market are expected to boost the global market growth in the forecast period. For instance, in August 2022, Myneurva, a global leader in computational QEEG analysis introduced Starrbase, a completely integrated system advanced neural network analysis EEG device.

Moreover, in November 2021, Brain Scientific's Next-Gen NeuroCap EEG Headset, an avant-garde Electroencephalogram (EEG) electrode array employed to acquire quick EEGs in routine clinical and research environments where the recording of STAT EEGs acquired the United States Food and Drug Administration approval. Again, in September 2022, the United States Food and Drug Administration (FDA) awarded Breakthrough Device Designation for Ceribell, Inc.'s delirium indication, the system employs machine learning to examine electroencephalography (EEG) signals to diagnose delirium.

Further, in October 2022, Nihon Kohden launched the Smart Cable NMT Pod and disposable electrode, an instrument with the Smart Cable Procedure. The development allows clinicians to precisely scan the patient's profundity of paralysis at the moment of surgery when a neuromuscular blockade agent (NMBA), both depolarizing or non-depolarizing, is given to the patient.

High Electroencephalography Device Cost

The cost of the device varies based on its features sensitivity, precision, and modality. For instance, the lower price range ($99 - $1,000), begins with the lowest quantity of electrodes. Few corporations such as NeuroSky and Muse promise neurofeedback and offer lower-cost solutions to assist in improving meditation and sleep, despite the research potential. While, the middle price range ($1,000 - $25,000), offers more available electrodes for each device, and additional bonuses to the hardware units. All of the devices within this price range are research-grade, however, the precise nature of the study will specify which unit is best suitable for the purpose.

Many companies (ABM, ANT Neuro, Cognionics, G.tec, mBrainTrain, Neuroelectrics, and Wearable Sensing) present wireless devices at this price scope, facilitating data collection to happen with improved mobility and increased comfort. Furthermore, the upper price range ($25,000+), offers a large number of electrode channels starting at 32 with Brain Product's ActiCHamp and resuming up to 160, or even 256 channels with BioSemi. This abundance of electrodes permits an exceptionally increased resolution when detecting brain signals. However, the high cost of these devices makes it difficult for low-income practices to afford them, decreasing high-end devices market demand and slowing the market growth.

Neurologists Workforce Shortage

The extensive neurologist workforce gaps are expected to hamper the global electroencephalography devices market growth during the forecast. For instance, the data published by the Association of British Neurologists (ABN) indicates that the UK's workforce of adviser neurologists is extremely down than might be anticipated. In comparison to France and Germany, the UK workforce is largely inferior, even in London and the neighboring places where ratios of patient to adviser are sounder. The ABN performed a workforce survey lately, surveying nearly half of all consultant neurologists accounting for 46% of the total, and over a third of neurology trainees which is 35% of the total.

Also, the ABN discovered that the number of full-time equivalent (FTE) neurology advisors concerned with patient assistance sits at a ratio of 1.1 per 100,000, or 1 per 91,175 inhabitants. This is invariant of the fact that the UK has a moderately adequate density of medical physicians over the board, estimated by the World Health Organisation (WHO) as 28 per 10,000 of the inhabitants. Moreover, in 2019, there were merely 400 open neurology provider appointments. That number has risen greatly to the point that by 2025 there is estimated to be a 19% gap in the neurologist workforce.

Segment Analysis

The global electroencephalography devices market is segmented based on product type, number of channels, signal frequency, procedure, application, end-user and region.

Portable EEG Devices Expected to Dominate Market

The Portable EEG devices are expected to hold a prominent share of the global market in the forecast period owing to the increasing number of product approvals and investments in the segment. For instance, in August 2023, Ceribell, Inc.'s new software ClarityPro secured 510(k) approval from the U.S. Food and Drug Administration (FDA) for the presentation of diagnosing Electrographic Status Epilepticus (ESE).

The approval tracks the preliminary receipt of Breakthrough Device Designation from the FDA. Following obtaining Breakthrough Device Designation and 510(k) approval from the FDA, the U.S. Centers for Medicare and Medicaid Services (CMS) awarded a New Procedure Add-on Payment (NTAP) for ClarityPro of around $913.90 per eligible Medicare patient case. Ahainr, in May 2023, the FDA awarded 510(k) approval to Cumulus Neuroscience's novel, dry-sensor EEG headset, a user-friendly device that allows self-directed usage and produces clinical-grade data for remote physician assessment.

The Cumulus EEG device, developed for both adult and adolescent individuals is obtainable in 4 measures and is effortlessly self-applied in not more than 5 minutes with direction from the Cumulus mobile app, therefore eliminating the requirement for EEG technician or healthcare professional aid. The platform unites clinical-grade, at-home data with machine learning analytics and a large real-world database of annotated, longitudinal, matched data.

Geographical Penetration

Increasing Number of Neurological Disorders Cases in North America

The growing number of neurological cases in this region along with funding from government associations for research activities in neurology are expected to boost the North American market growth dominating the global market throughout the forecast period. For instance, according to the statistics from the Alzheimer's Association, almost 6.5 million Americans aged 65 years and older were expected to be suffering from Alzheimer's in 2022 and 73% were of age 75 or older which are at more elevated risk or developing the disorder.

Moreover, according to the information from the ALS Association, by 2050, around 12.7 million individuals aged 65 and older are estimated to suffer from Alzheimer's. Further, the estimates from the National Vital Statistics Report gathered by the Centers for Disease Control and Prevention (CDC) demonstrate that stroke was the fifth among the foremost reasons of death in the U.S.

The statistics from the same source indicate that the moderate years of potential life lost under 75 years of age owing to cerebrovascular disorders was 187.1 in the U.S. In addition, the National Institute of Neurological Disorders and Stroke (NINDS) in the U.S. funds investigations into neurological disorders their diagnosis, and treatment along with raising public understanding of neurological conditions.

Furthermore, new product introductions into the North American Electroencephalography Devices market also contribute to the regional market growth. For instance, in August 2021, Natus Medical, a top provider of medical device developments in the U.S., successfully conducted a clinical trial by utilizing Natus' recently introduced XactTrode family of platinum subdural electrodes which are expected to be employed for Epilepsy Surgical Monitoring.

COVID-19 Impact Analysis

During the COVID-19 pandemic, elective and routine examinations and operations were postponed or discontinued because of redirecting aids to additional emergent therapy for extremely sick individuals and to avert the spread and contraction of COVID-19. Additionally, the workforce was pulled narrow, and healthcare structures witnessed growing turnover rates for full-time and agreement workers, which pushed the system and decreased the capacity to deliver clinical assistance.

One of the losses of these shifts was electroencephalography (EEG) practices, which have been conducted less repeatedly all over the globe since the pandemic. Whether assumed standard or emergent, the deferral of EEG studies caused downstream consequences, such as the delay in diagnosis and beginning treatment for epilepsy and non-epileptic episodes inducing a more raised threat of morbidity and mortality.

Regardless of these restrictions, the significance and benefits of EEG and EEG approaches have been re-enacted with the evolution of COVID-associated neurological intricacies, such as encephalopathy and seizures, which need EEG for detection and treatment. Further, since the pandemic, dependence on remote telemonitoring emphasized the importance and comfort of utilizing EEG. There has also been an elevated interest in quick EEG devices that non-technologist experts can connect fast, permitting the lowest patient contact to evade vulnerability to COVID-19 and enduring the benefit of remote EEG monitoring.

Russia-Ukraine Impact

The war in Ukraine has caused staggering casualties, an exceptional refugee situation, and devastation of infrastructure including infirmaries and basic needs reserves depletion. The war has even damaged the delivery of medical care. Considerable provincial medical bases have individually documented thousands of trauma case entries from February 2022. The scarcity of dependable air transportation leaves the logistics for health care significantly difficult.

Extreme disturbances to multinational markets generated by Russia's war on Ukraine have revealed susceptibilities to the safety of the supply of raw materials necessary for industrial production and for the green transition. These supply chain exposures are the consequences of export restrictions, bilateral dependences, a deficiency of clarity, and constant market asymmetries, including the engagement of production in only a few nations. For nations influenced by supply chain susceptibilities, there are possibilities to diversify sourcing via extended production and accessing comprehended critical raw materials resources.

By Product Type

Portable
Tabletop
Wireless

By Number of Channels

8-channel EEG
21-channel EEG
25-channel EEG
32-channel EEG
40-channel EEG
Multi-channel EEG

By Signal Frequency

3 Hz or below
3.5 to 7.5 Hz
7.5 and 13 Hz
14 and greater Hz

By Procedure

Routine EEG
Sleep-Deprived EEG
Ambulatory EEG
Others

By Application

Disease Diagnosis
Sleep Monitoring
Anesthesia Monitoring
Trauma and Surgery
Others

By End-User

Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Diagnostic Centers
Academic and Research Organizations
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In February 2022, Masimo obtained the United States Food and Drug Administration authorization of pediatric indication for SedLine brain operation monitoring and the SedLine pediatric EEG sensor.
In March 2022, Interaxon Inc. introduced a VR Software Development Kit (SDK) with a new EEG headband compatible with all major VR head-mounted displays (HMDs), producing Interaxon's second-generation EEG meditation and sleep headband.
In 2022, Natus Medical Inc. introduced its latest BrainVision EEG software, a fresh platform developed to improve the precision and efficiency of EEG testing. The software encloses a grade of unique features, including automated artifact detection, combined source localization, and a unique user interface developed to assemble EEG testing additional instinctive and user-friendly.

Competitive Landscape

The major global players in the market include: EMS Handels Gesellschaft m.b.H., KONINKLIJKE PHILIPS N.V., Medtronic, Allengers, EB NEURO S.P.A., Shenzhen Delica Medical Equipment Co., Ltd., Micromed Group, NIHON KOHDEN CORPORATION, Cadwell , Natus Medical Incorporated and Icare USA among others.

Why Purchase the Report?

To visualize the global electroencephalography devices market segmentation based on product type, number of channels signal frequency, procedure, application, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of electroencephalography devices market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key product of all the major players.

The global electroencephalography devices market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Number of Channels
3.3. Snippet by Signal Frequency
3.4. Snippet by Procedure
3.5. Snippet by Application
3.6. Snippet by End-User
3.7. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Neurological Disorders
  - 4.1.1.2. Increasing Number of Product Approvals and Launches
- 4.1.2. Restraints
  - 4.1.2.1. High Electroencephalography Device Cost
  - 4.1.2.2. Neurologists Workforce Shortage
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. Technology Trend
5.7. End-User Trend
5.8. SWOT Analysis
5.9. Russia-Ukraine War Impact
5.10. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Portable*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Tabletop
- 7.2.4. Wireless

8. By Number of Channels

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.1.2. Market Attractiveness Index, By Product Type
8.2. 8-channel EEG*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.2.3. 21-channel EEG
- 8.2.4. 25-channel EEG
- 8.2.5. 32-channel EEG
- 8.2.6. 40-channel EEG
- 8.2.7. Multi-channel EEG

9. By Signal Frequency

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signal Frequency
- 9.1.2. Market Attractiveness Index, By Signal Frequency
9.2. 3 Hz or below*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.2.3. 3.5 to 7.5 Hz
- 9.2.4. 7.5 and 13 Hz
- 9.2.5. 14 and greater Hz

10. By Procedure

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.1.2. Market Attractiveness Index, By Procedure
10.2. Routine EEG*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Sleep-Deprived EEG
10.4. Ambulatory EEG
10.5. Others

11. By Application

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.1.2. Market Attractiveness Index, By Application
11.2. Disease Diagnosis*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Sleep Monitoring
11.4. Anesthesia Monitoring
11.5. Trauma and Surgery
11.6. Others

12. By End-User

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.1.2. Market Attractiveness Index, By End-User
12.2. Hospitals*
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Specialty Clinics
12.4. Ambulatory Surgical Centers
12.5. Diagnostic Centers
12.6. Academic and Research Organizations
12.7. Others

13. By Region

13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Number of Channels
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signal Frequency
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.2.9.1. U.S.
  - 13.2.9.2. Canada
  - 13.2.9.3. Mexico
13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Number of Channels
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signal Frequency
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 13.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.3.9.1. Germany
  - 13.3.9.2. UK
  - 13.3.9.3. France
  - 13.3.9.4. Italy
  - 13.3.9.5. Spain
  - 13.3.9.6. Rest of Europe
13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Number of Channels
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signal Frequency
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 13.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.4.9.1. Brazil
  - 13.4.9.2. Argentina
  - 13.4.9.3. Rest of South America
13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Number of Channels
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signal Frequency
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 13.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.5.9.1. China
  - 13.5.9.2. India
  - 13.5.9.3. Japan
  - 13.5.9.4. Australia
  - 13.5.9.5. Rest of Asia-Pacific
13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Number of Channels
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Signal Frequency
- 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 13.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

14. Competitive Landscape

14.1. Competitive Scenario
14.2. Market Positioning/Share Analysis
14.3. Mergers and Acquisitions Analysis

15. Company Profiles

15.1. EMS Handels Gesellschaft m.b.H.*
- 15.1.1. Company Overview
- 15.1.2. Product Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
15.2. KONINKLIJKE PHILIPS N.V.
15.3. Medtronic
15.4. Allengers
15.5. EB NEURO S.P.A.
15.6. Shenzhen Delica Medical Equipment Co., Ltd.
15.7. Micromed Group
15.8. NIHON KOHDEN CORPORATION
15.9. Cadwell
15.10. Natus Medical Incorporated

LIST NOT EXHAUSTIVE

16. Appendix

16.1. About Us and Services
16.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格